https://www.databridgemarketresearch.com/reports/global-next-generation-rsv-drug-and-vaccine-market

BCG Vaccine Market to Grow at 3.3% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global Bacille Calmette-Guerin vaccine market was valued at USD 73.4 million in 2024 and is projected to reach USD 91.7 million by 2031, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2025-2031. Bacille Calmette-Gurin (BCG) vaccine, a live-attenuated strain derived from Mycobacterium bovis, remains the world's most widely administered vaccine for tuberculosis prevention and stands as a cornerstone in global immunization programs. Its primary role involves protecting infants and young children in regions with high TB prevalence from severe forms of the disease, including military TB and TB meningitis. While its efficacy against pulmonary TB in adults shows limitations, its established protective benefits for pediatric populations ensure its continued relevance in public health strategies worldwide. Beyond TB prevention, the vaccine has gained significant therapeutic importance in oncology, particularly for the treatment of non-muscle-invasive bladder cancer, representing a vital secondary application that diversifies its market value. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3756/bacille-calmette-guerin-vaccine-market

Self Amplifying RNA Vaccine Market to Grow at 6.1% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global self-amplifying RNA vaccine market was valued at USD 381 million in 2024 and is projected to reach USD 550 million by 2031, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2025–2031. Self-amplifying RNA vaccines represent an advanced iteration of mRNA technology, distinguished by their ability to replicate within host cells after administration. Unlike conventional mRNA vaccines, saRNA vaccines contain replicase genes that enable self-amplification, producing significantly higher antigen levels with lower initial doses. This technology offers advantages in pandemic response through dose-sparing strategies, broad-spectrum immunity against viral variants, and rapid development timelines comparable to mRNA platforms while addressing stability challenges through optimized lipid nanoparticle formulations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5170/self-amplifying-rna-vaccine-market

https://www.databridgemarketresearch.com/reports/global-aquaculture-vaccine-market